AI drug discovery startup Ozette Technologies has raised USD 26 million in a Series A funding round led by Madrona Ventures with participation from Cercano Management, M12 (Microsoft’s venture fund), and others.
The proceeds will be directed toward advancing the capabilities of its technology with single-cell proteomics and transcriptomics. It will also be used to fuel the company’s growth efforts.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.